UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Clinical cancer research, 2024-06, Vol.30 (11), p.2531

2024

Volltextzugriff (PDF)

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Molecular oncology, 2024-03, Vol.18 (3), p.726-742

2024

Volltextzugriff (PDF)

GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer

International journal of molecular sciences, 2023-12, Vol.25 (1), p.489

2023

Volltextzugriff (PDF)

Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

Cancer research (Chicago, Ill.), 2023-06, Vol.83 (11_Supplement), p.B065-B065

2023

Volltextzugriff (PDF)

Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5047-5047

2023

Volltextzugriff (PDF)

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2289

2023

Volltextzugriff (PDF)

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2189

2023

Volltextzugriff (PDF)

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

Cancers, 2022-12, Vol.15 (1), p.2

2022

Volltextzugriff (PDF)

Abstract 3311: Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3311-3311

2022

Volltextzugriff (PDF)

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.651-651

2022

Volltextzugriff (PDF)

From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer

International journal of molecular sciences, 2022-06, Vol.23 (11), p.6281

2022

Volltextzugriff (PDF)

18nm FDSOI Enhanced Device Platform for ULP/ULL MCUs

2022 International Electron Devices Meeting (IEDM), 2022, p.27.2.1-27.2.4

2022

Volltextzugriff (PDF)

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Clinical cancer research, 2021-08, Vol.27 (15), p.4367-4378

2021

Volltextzugriff (PDF)

Abstract 1008: Comparative proteomics and transcriptomics analysis of the impact of androgen stimulation and darolutamide inhibition in a prostate cancer model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1008-1008

2021

Volltextzugriff (PDF)

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Cellular oncology (Dordrecht), 2021-06, Vol.44 (3), p.581-594

2021

Volltextzugriff (PDF)

Targeting DNA Damage Response in Prostate and Breast Cancer

International journal of molecular sciences, 2020-11, Vol.21 (21), p.8273

2020

Volltextzugriff (PDF)

Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation

Molecular oncology, 2020-09, Vol.14 (9), p.2022-2039

2020

Volltextzugriff (PDF)

Abstract 5353: PSMA-targeted thorium conjugate and darolutamide combination show synergistic anti-tumor activity and reduced expression of DNA damage repair genes in prostate cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5353-5353

2020

Volltextzugriff (PDF)

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target

Cancers, 2020-01, Vol.12 (1), p.201

2020

Volltextzugriff (PDF)

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.26-38

2020

Volltextzugriff (PDF)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

International journal of cancer, 2019-09, Vol.145 (5), p.1382-1394

2019

Volltextzugriff (PDF)

Abstract 924: The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.924-924

2019

Volltextzugriff (PDF)

Abstract 5210: Darolutamide impairs prostate cancer growth by altering chromatin conformation and transcriptional activity of genes involved in cell proliferation and survival

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.5210-5210

2019

Volltextzugriff (PDF)

Dysregulated Transcriptional Control in Prostate Cancer

International journal of molecular sciences, 2019-06, Vol.20 (12), p.2883

2019

Volltextzugriff (PDF)

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

Nature medicine, 2018-10, Vol.24 (10), p.1599-1610

2018

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(117)
Tagungsberichte
(1)

Sprache

Englisch
(118)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(67)
Humans
(58)
Animals
(47)
Biochemistry & Molecular Biology
(30)
Male
(28)
Gene Expression
(22)
Mice
(21)
Molecular Sequence Data
(20)
Prostate Cancer
(20)
Amino Acid Sequence
(19)
Biological And Medical Sciences
(19)
Female
(18)
Androgen Receptor
(16)
Base Sequence
(16)
Cell Biology
(15)
Fundamental And Applied Biological Sciences. Psychology
(15)
Mutation
(14)
Oncology
(14)
Proteins
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer

Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

Abstract 3311: Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer

18nm FDSOI Enhanced Device Platform for ULP/ULL MCUs

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Abstract 1008: Comparative proteomics and transcriptomics analysis of the impact of androgen stimulation and darolutamide inhibition in a prostate cancer model

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Targeting DNA Damage Response in Prostate and Breast Cancer

Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation

Abstract 5353: PSMA-targeted thorium conjugate and darolutamide combination show synergistic anti-tumor activity and reduced expression of DNA damage repair genes in prostate cancer models

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Abstract 924: The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models

Abstract 5210: Darolutamide impairs prostate cancer growth by altering chromatin conformation and transcriptional activity of genes involved in cell proliferation and survival

Dysregulated Transcriptional Control in Prostate Cancer

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

Suchergebnisse filtern